Enhertu is already approved or has accelerated approval for the treatment of several cancers involving HER mutations, including breast cancer, non-small cell lung cancer, gastroesophageal junction ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

The safety profile of Enhertu was similar to that seen in previous studies for breast cancer indications. Enhertu — A Key Oncology Drug for AZN Enhertu, a specifically engineered HER2-directed ...

The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of the DESTINY-Breast06 trial, one of the highlights of this year's ASCO congress, which enrolled patients ...

We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung cancer cell line. Single guide RNAs (sgRNAs) designed and ...

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non ...

Lola McEvoy is set to press the government upon the use of Enhertu after the death of Heather Sawyer - a Darlington grandmother who campaigned for the drug she believed would have extended her life.